Improved functional and morphological outcomes with faricimab in nAMD eyes with poor response to prior intravitreal anti-VEGF therapy
The findings suggest Faricimab as an effective option for nAMD patients who respond inadequately to prior anti-VEGF therapies, offering both functional and anatomical improvements. Extended intervals reduce treatment burden, indicating faricimab's potential to enhance disease control and patient quality of life in real-world settings.
Authors
- Nathalie Bleidißel
- Nikolaus Feucht (ORCID: https://orcid.org/0000-0001-9848-0070)
- Mathias M. Maier (ORCID: https://orcid.org/0000-0003-4165-4003)
- Mario Weichenberger
- Nina Spielberg
Institutions
- Manchester Airport (GB)
- TUM Klinikum (DE)
Publication Details
- Journal
- International Ophthalmology
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1007/s10792-025-03525-2
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.41
Funders
- Technische Universität München